In another hematological neoplasm, mantle cell lymphoma (MCL), casein kinase 2 (CK2) has been shown to be over-expressed, and targeting CK2 reduces MCL-1 levels, which in turn sensitizes MCL cells to BCL-2-specific venetoclax inhibitor and presents a novel therapeutic strategy for MCL patients [11]. Here, BCL2 is linked to mantle cell lymphoma.